3.0.0 7828 2022-12-30T00:04:02Z 2022-12-30T00:04:02Z House HR 2022-05-18 117 [Congressional Record Volume 168, Number 85 (Wednesday, May 18, 2022)][House][Pages H5174-H5175]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Ms. SCHAKOWSKY:H.R. 7828.Congress has the power to enact this legislation pursuantto the following:[[Page H5175]]Article I, Section 8, Clause 3]]> hsif00 Energy and Commerce Committee House Standing Referred to 2022-05-18T16:00:35Z Affordable Medications Act 117 1898 S 2021-05-27 Read twice and referred to the Committee on Finance. Related bill CRS Fair Care Act of 2022 117 8588 HR 2022-11-01 Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. Related bill CRS 2022-05-18 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2022-05-18 Introduced in House IntroReferral Intro-H 9 Library of Congress 2022-05-18 Introduced in House IntroReferral 1000 9 Library of Congress S001145 Rep. Schakowsky, Janice D. [D-IL-9] JANICE SCHAKOWSKY D IL D. 9 N W000821 Rep. Westerman, Bruce [R-AR-4] Bruce Westerman R AR 4 2022-05-18 True K000389 Rep. Khanna, Ro [D-CA-17] Ro Khanna D CA 17 2022-05-18 True D000399 Rep. Doggett, Lloyd [D-TX-35] LLOYD DOGGETT D TX 35 2022-05-18 True P000607 Rep. Pocan, Mark [D-WI-2] Mark Pocan D WI 2 2022-05-18 True K000009 Rep. Kaptur, Marcy [D-OH-9] MARCY KAPTUR D OH 9 2022-05-18 True G000586 Rep. Garcia, Jesus G. "Chuy" [D-IL-4] Jesus Garcia D IL G. 4 2022-05-18 True D000216 Rep. DeLauro, Rosa L. [D-CT-3] ROSA DELAURO D CT 3 2022-05-18 True K000391 Rep. Krishnamoorthi, Raja [D-IL-8] Raja Krishnamoorthi D IL 8 2022-05-24 False L000592 Rep. Levin, Andy [D-MI-9] Andy Levin D MI 9 2022-07-12 False J000298 Rep. Jayapal, Pramila [D-WA-7] Pramila Jayapal D WA 7 2022-07-12 False Health Health 00 2022-05-18 Introduced in House 2022-10-18T14:53:32Z Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

]]> PRICED Act Display Title PRICED Act Short Title(s) as Introduced PRICED Act Introduced in House IH Short Title(s) as Introduced Price Relief, Innovation, and Competition for Essential Drugs Act Introduced in House IH Official Title as Introduced To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years. Introduced in House IH Introduced in House 2022-05-18T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-117hr7828ih/xml/BILLS-117hr7828ih.xml 2022-05-18 Referred to the House Committee on Energy and Commerce. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.